Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV

被引:231
|
作者
Drucker, DJ
Shi, Q
Crivici, A
SumnerSmith, M
Tavares, W
Hill, M
DeForest, L
Cooper, S
Brubaker, PL
机构
[1] UNIV TORONTO,TORONTO HOSP,DEPT PHYSIOL,BANTING & BEST DIABET CTR,TORONTO,ON,CANADA
[2] ALLELIX BIOPHARMACEUT INC,MISSISSAUGA,ON,CANADA
关键词
protein modeling; protease inactivation; growth factor; intestine; therapeutic;
D O I
10.1038/nbt0797-673
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-5 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV), GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats, Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly(2)]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild-type rats with r[Gly(2)]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-5 is a critical determinant of the growth factor-like properties of GLP-2.
引用
收藏
页码:673 / 677
页数:5
相关论文
共 50 条
  • [1] Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
    Daniel J. Drucker
    Qing Shi
    Anna Crivici
    Martin Sumner-Smith
    Wendy Tavares
    Mary Hill
    Lorraine DeForest
    Sari Cooper
    Patricia L. Brubaker
    [J]. Nature Biotechnology, 1997, 15 : 673 - 677
  • [2] Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV
    Hansen, Lene
    Hare, Kristine J.
    Hartmann, Bolette
    Deacon, Carolyn F.
    Ugleholdt, Randi K.
    Plamboeck, Astrid
    Holst, Jens J.
    [J]. REGULATORY PEPTIDES, 2007, 138 (2-3) : 126 - 132
  • [3] A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro
    Lambeir, AM
    Proost, P
    Scharpé, S
    De Meester, I
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (12) : 1753 - 1756
  • [4] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1: In vitro and in vivo studies
    Deacon, CF
    Knudsen, LB
    Johansen, NL
    Madsen, K
    Holst, JJ
    [J]. DIABETOLOGIA, 1997, 40 : 492 - 492
  • [5] Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
    Holst, JJ
    Deacon, CF
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2004, 4 (06) : 589 - 596
  • [6] The degradation of glucagon-like peptide-1 involves both dipeptidyl peptidase IV and neutral endopeptidase 24.11 in vivo
    Plamboeck, A
    Holst, JJ
    Carr, RD
    Deacon, CF
    [J]. REGULATORY PEPTIDES, 2004, 122 (01) : 6 - 6
  • [7] Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1
    Deacon, CF
    Hughes, TE
    Holst, JJ
    [J]. DIABETES, 1998, 47 : A69 - A69
  • [8] Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 rats and mice
    Hartmann, B
    Thulesen, J
    Kissow, H
    Thulesen, S
    Orskov, C
    Ropke, C
    Poulsen, SS
    Holst, JJ
    [J]. ENDOCRINOLOGY, 2000, 141 (11) : 4013 - 4020
  • [9] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
    C. F. Deacon
    L. B. Knudsen
    K. Madsen
    F. C. Wiberg
    O. Jacobsen
    J. J. Holst
    [J]. Diabetologia, 1998, 41 : 271 - 278
  • [10] Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity
    Deacon, CF
    Knudsen, LB
    Madsen, K
    Wiberg, FC
    Jacobsen, O
    Holst, JJ
    [J]. DIABETOLOGIA, 1998, 41 (03) : 271 - 278